HomeCompareARTLW vs NOBL

ARTLW vs NOBL: Dividend Comparison 2026

ARTLW yields 35714.29% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARTLW wins by $1.6752839315172392e+22M in total portfolio value
10 years
ARTLW
ARTLW
● Live price
35714.29%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6752839315172392e+22M
Annual income
$16,661,069,746,468,538,000,000,000,000.00
Full ARTLW calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — ARTLW vs NOBL

📍 ARTLW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARTLWNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARTLW + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARTLW pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARTLW
Annual income on $10K today (after 15% tax)
$3,035,714.29/yr
After 10yr DRIP, annual income (after tax)
$14,161,909,284,498,257,000,000,000,000.00/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, ARTLW beats the other by $14,161,909,284,498,257,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARTLW + NOBL for your $10,000?

ARTLW: 50%NOBL: 50%
100% NOBL50/50100% ARTLW
Portfolio after 10yr
$8.376419657586196e+21M
Annual income
$8,330,534,873,234,269,000,000,000,000.00/yr
Blended yield
99.45%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARTLW buys
0
NOBL buys
0
No recent congressional trades found for ARTLW or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARTLWNOBL
Forward yield35714.29%2.14%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.6752839315172392e+22M$22.8K
Annual income after 10y$16,661,069,746,468,538,000,000,000,000.00$246.19
Total dividends collected$1.6746806834400388e+22M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ARTLW vs NOBL ($10,000, DRIP)

YearARTLW PortfolioARTLW Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$3,582,129$3,571,428.57$10,914$214.34+$3.57MARTLW
2$1,199,469,917$1,195,637,039.86$11,897$218.63+$1199.46MARTLW
3$375,448,961,128$374,165,528,316.29$12,952$222.72+$375448.95MARTLW
4$109,858,226,763,271$109,456,496,374,863.77$14,086$226.62+$109858226.75MARTLW
5$30,049,803,731,826,150$29,932,255,429,189,452.00$15,302$230.33+$30049803731.81MARTLW
6$7,683,972,846,060,485,000$7,651,819,556,067,430,000.00$16,607$233.85+$7683972846060.47MARTLW
7$1,836,848,834,513,013,000,000$1,828,626,983,567,728,800,000.00$18,007$237.18+$1836848834513013.00MARTLW
8$410,500,120,243,639,900,000,000$408,534,691,990,711,000,000,000.00$19,508$240.35+$410500120243639936.00MARTLW
9$85,765,952,059,675,500,000,000,000$85,326,716,931,014,800,000,000,000.00$21,116$243.35+$85765952059675492352.00MARTLW
10$16,752,839,315,172,392,000,000,000,000$16,661,069,746,468,538,000,000,000,000.00$22,841$246.19+$1.6752839315172392e+22MARTLW

ARTLW vs NOBL: Complete Analysis 2026

ARTLWStock

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Full ARTLW Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this ARTLW vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARTLW vs SCHDARTLW vs JEPIARTLW vs OARTLW vs KOARTLW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.